Department of Molecular Oncology
Department head: Professor Ragnhild A. Lothe
Deputy department head: Professor Rolf I. Skotheim
Laboratory manager: Ina Andrassy Eilertsen
Department administrative consultant: Ikram Mahnin
As a research department within the OUH Comprehensive Cancer Centre, it is our responsibility and goal to accomplish high quality and interdisciplinary biomedical research for improved precision medicine and management of cancer patients.
Research groups
| Genetics | Genome Biology | Epigenetics |
|
|
|
Project groups
| Computational Oncology | Cell Signalling | Functional Precision Oncology | Cancer Informatics |
|
|
|
|
2023 – Experimental diagnostics enters the clinic
2022 – Translational research enters the clinic
2021 – 15th Anniversary of Dept. Molecular Oncology
The year 2020
Scientific achievements in 2019
About
Our main research programs are devoted to colorectal cancer and prostate cancer, and we have a longstanding project portfolio also on other solid tumor types. Our expertise in biomedical research spans several disciplines from cell biology to translational research, including also active clinical research collaborations, and we have a broad range of advanced technologies established in-lab. The department scientists are inventors of several biomedical patents and active innovation projects.
Lothe lab – genetics, genomics, cell signaling, colorectal cancer, MPNST, tumor heterogeneity, pharmacogenomics, biomarkers
Skotheim lab – genome biology, bioinformatics, tumor heterogeneity, prostate cancer, ovarian cancer, testicular cancer
Lind lab – epigenetics, genetics, GI-cancers, bladder cancer, early detection, monitoring
Affiliations
All three group leaders are adjunct professors at the University of Oslo and are affiliated with the Institute for Clinical Medicine, the Institute for Biosciences and the Institute for Informatics. We aim to complete at least 3 academic degrees annually, and since the inauguration of the Department in 2006, 75 MSc/PhD degrees have successfully been defended.
The research groups are partners of the Oslo University Hospital strategic research area - Precision colorectal cancer therapy, colorectal cancer COST – actions, The Global Testicular Cancer Consortium, The European network for study on Cholangiocarcinoma, a European multicenter study on MPNST (malignant peripheral nerve sheath tumor), The Norwegian Esophageal Cancer Consortium